Match!
Magyar onkologia
Papers
1148
Papers 1232
1 page of 124 pages (1,232 results)
Newest
#1Eszter Molnár (Semmelweis University)H-Index: 14
Targeted therapy for V600 BRAF mutant solid tumors already exists but resistance to the treatment is still a serious problem to be solved. Moreover, there are currently no approved targeted therapeutic options against non-V600 BRAF mutant tumors. Here we studied targeted therapy resistance mechanisms of V600 BRAF mutant melanoma and also explored potential alternative solutions for their treatment. In V600 BRAF mutant melanoma cells that did not or slightly express PTEN protein, prenylation inhi...
During colorectal cancer (CRC) development, in addition to genetic alterations, several epigenetic changes, including DNA methylation in the promoter regions accumulate in tumor cells. Cell-free DNA (cfDNA) in the circulatory system can originate also from tumor tissue; therefore the evaluation of methylated cfDNA in the plasma can be a promising method for early cancer screening. In my Ph.D., I have investigated the rate of cfDNA's release and stability using animal models. I aimed to compile a...
#1Gabriella Vizin (ELTE: Eötvös Loránd University)H-Index: 3
#2Kinga Farkas (Semmelweis University)H-Index: 2
Cancer is a huge psychological difficulty both for the patient and the caregivers. Patients often suffer from hopelessness, helplessness, depression, anxiety or other psychological disturbances. Although the cognitive behavioral interventions (cognitive behavioral therapy, mindfulness) are evidence based, short, time-limited, focused treatments for patients with cancer, in Hungary there are only little evidence and experiences about application of cognitive behavioral methods in the oncological ...
#1Vanessza Szabó (Semmelweis University)H-Index: 3
Treatment of patients with lung metastases remains a major challenge. A possible target for therapies is the inhibition of vascularization of metastases. We examined the vascularisation process of lung metastasis in six different preclinical models and found that the tumours incorporated the pre-existing alveolar capillaries (i.e. vessel co-option). During the initial phase of vessel co-option, the incorporated capillaries were still sheathed by pneumocytes, but these incorporated vessels subseq...
#2Béla MeleghH-Index: 37
Last. Kinga HadzsievH-Index: 9
view all 3 authors...
In the past few years there is an emerging need for clinical genetics counseling in the case of malignant diseases as well. For these reasons a novel professional recommendation has been developed for oncogenetic counseling, whose publication is in progress. In nearly 10% of childhood cancers there is an underlying tumor predisposition syndrome, but this value is thought to be underestimated. Due to the treatment of these cancers and the risk of a possible new developing tumor, genetic counselin...
#1Lili Kotmayer (Semmelweis University)
#2Krisztián KállayH-Index: 4
Last. Csaba Bödör (Semmelweis University)H-Index: 17
view all 3 authors...
The majority of haematological malignancies represent sporadic diseases, but hereditary entities with predisposing genetic alterations have also been described. Diseases of the myeloid and lymphoid cell lineages with genetic predispositions are associated with heterogeneous clinical manifestations, with many symptoms being specific for certain cytogenetic and molecular aberrations. Apart from the myeloid predisposition syndromes with clear Mendelian inheritance patterns, cases with ambiguous pre...
Based on our current knowledge, 5-10% of all malignancies are part of hereditary cancer syndromes. Although the increasing diagnostic role of molecular genetic testing makes us able to recognize more hereditary cancer patients, the careful exploration of family and clinical history by physicians is still the most important step for the diagnosis. In our review we deal with mesenchymal tumours associated with hereditary syndromes. Sarcomas comprise only 1% of all malignancies, but they often asso...
#1Zsuzsanna Kahán (University of Szeged)H-Index: 17
Germinal or somatic mutations of the BRCA genes may serve as therapeutic targets. Deficient functioning of the BRCA genes render the cancer vulnerable to such therapeutic interventions as chemotherapy with DNA-targeted agents and PARP inhibitors targeting DNA repair capacity. Although BRCA mutations may be detected in a large variety of cancers, the mentioned specific therapies are efficient in the so called BRCA-associated cancers only including ovarian, breast, pancreatic, prostate cancers and...
The technical developments lead to revolution and speed-up of molecular genetic diagnostics of hereditary cancer syndromes. In those apparently sporadic, solid tumors where the chance of inheritance is higher than 10%, the molecular genetic analysis is indicated. Nowadays these tests are performed using next generation sequencing technologies which allow parallel testing of multiple genes. However, in well-defined cancer syndromes where the clinical presentation clearly suggests the diagnosis an...
Inherited colorectal cancer syndromes account for 6-10% of all cases. The diagnosis of the polypoid forms is easier due to their phenotypes, compared to the non-polypoid cases. The evaluation of the MSI/MMR status of the already developed colorectal cancer cases could help in the recognition and screening of the latter forms. This screening method is much more sensitive than that solely based on family anamnestic data. The MSI/MMR status of the tumor also could help in adjuvant or palliative tre...
12345678910
Top fields of study
Cancer
Oncology
Cancer research
Breast cancer
Medicine